Literature DB >> 2769536

Cholangitis after the Kasai operation for biliary atresia.

S S Rothenberg1, G P Schroter, F M Karrer, J R Lilly.   

Abstract

One hundred seventy-nine episodes of cholangitis in 28 consecutive patients having a Kasai operation for biliary atresia during the past 3 1/2 years were analyzed. The diagnosis was made primarily on the basis of unexplained fever (greater than 38.0 degrees C). An increase in serum bilirubin or a decrease in bile volume and in bile bilirubin concentration were often confirmatory, but other laboratory data including serum hepatic enzymes and blood and bile culture data were of little or inconsistent value. All patients were treated with systemic antibiotics. The best results were obtained with third-generation cephalosporins or imipenemcilastatin with the addition of aminoglycosides in recalcitrant cases. Antibiotic therapy was modified if defervescence did not occur within the first 24 hours. Cholangitis refractory to antibiotics was aggressively treated with pulse steroid therapy, and in some cases, operative intervention, both with good clinical success (60% and 73%, respectively).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2769536     DOI: 10.1016/s0022-3468(89)80525-1

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  10 in total

1.  Periodic bile cultures and irrigation of the external jejunostomy for cholangitis in biliary atresia.

Authors:  E Deguchi; J Yanagihara; H Shinjo; N Iwai
Journal:  Pediatr Surg Int       Date:  2013-09-21       Impact factor: 1.827

2.  Efficacy of urinary sulfated bile acids for diagnosis of bacterial cholangitis in biliary atresia.

Authors:  Tsuyoshi Shinohara; Toshihiro Muraji; Chikara Tsugawa; Eiji Nishijima; Shiiki Satoh; Shigeru Takamizawa
Journal:  Pediatr Surg Int       Date:  2005-10-20       Impact factor: 1.827

3.  Unusual cases of acute cholecystitis and cholangitis: Tokyo Guidelines.

Authors:  Hideki Yasuda; Tadahiro Takada; Yoshifumi Kawarada; Yuji Nimura; Koichi Hirata; Yasutoshi Kimura; Keita Wada; Fumihiko Miura; Masahiko Hirota; Toshihiko Mayumi; Masahiro Yoshida; Masato Nagino; Yuichi Yamashita; Serafin C Hilvano; Sun-Whe Kim
Journal:  J Hepatobiliary Pancreat Surg       Date:  2007-01-30

4.  Bacteria ascend to liver from the bilioenteric conduit after choledochojejunostomy in the cholestatic rat.

Authors:  C S Hsieh; L-T Huang; C C Huang; J J Wu; J H Chuang
Journal:  Pediatr Surg Int       Date:  2003-10-15       Impact factor: 1.827

Review 5.  Biliary atresia: Indications and timing of liver transplantation and optimization of pretransplant care.

Authors:  Shikha S Sundaram; Cara L Mack; Amy G Feldman; Ronald J Sokol
Journal:  Liver Transpl       Date:  2017-01       Impact factor: 5.799

Review 6.  Biliary tract infections: a guide to drug treatment.

Authors:  J F Westphal; J M Brogard
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

7.  Emergency liver transplantation after Kasai portoenterostomy.

Authors:  M T Corbally; N Heaton; M Rela; G Mieli-Vergani; B Portmann; A Mowat; R Williams; K C Tan
Journal:  Arch Dis Child       Date:  1994-02       Impact factor: 3.791

8.  A valved hepatic portoduodenal intestinal conduit for biliary atresia.

Authors:  K Tanaka; I Shirahase; H Utsunomiya; T Katayama; S Uemoto; K Asonuma; Y Inomata; K Ozawa
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

9.  Antireflux Status Post Roux-en-Y anastomosis: An Experimental Study for Optimal Antireflux Technique.

Authors:  Ajay Kumar Verma; Om Prakash Purbey; Shiv Narain Kureel; Archika Gupta; Anand Pandey; Kanoujia Sunil; Digamber Chaubey
Journal:  J Indian Assoc Pediatr Surg       Date:  2018 Jan-Mar

10.  Number of cholangitis episodes as a prognostic marker to predict timing of liver transplantation in biliary atresia patients after Kasai portoenterostomy.

Authors:  Szu-Ying Chen; Chieh-Chung Lin; Yu-Tse Tsan; Wei-Cheng Chan; Jiaan-Der Wang; Yi-Jung Chou; Ching-Heng Lin
Journal:  BMC Pediatr       Date:  2018-04-02       Impact factor: 2.125

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.